ecancer
ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.
GU Cancers
ecancer
Radiation Therapy After Radical Surgery in Prostate Cancer
FEATURING
Roberto Paz
- 42 views
- July 10, 2023
ecancer
EAU 2022 Update on PC Screening: A Novel Risk Prediction Tool With Standard Biopsies vs. PSA With MRI-Targeted Biopsies
FEATURING
Lars Björnebo
- 36 views
- September 7, 2022
ecancer
Bladder Cancer: Current State and Future Directions in Treatment
FEATURING
Jorge Garcia
- 123 views
- September 7, 2022
- 1
ecancer
ASCO GU 2022 on the ATLANTIS Trial: Maintenance PARPi Following Chemo for mUC
FEATURING
Simon Crabb
- 22 views
- April 15, 2022
ecancer
ASCO GU 2022 Updates on the Survival Benefit of Cabo + Nivo in aRCC
FEATURING
Cristina Suárez
- 67 views
- April 15, 2022
ecancer
ASCO GU 2022: Latest Developments in mHSPC
FEATURING
Kurt Miller,
Laura-Maria Krabbe
- 26 views
- April 15, 2022
ecancer
ASCO GU 2022 Updates on the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma: The ADIUVO Study
FEATURING
Alfredo Berruti
- 64 views
- April 13, 2022
ecancer
ASCO GU 2022: PARPi in Prostate Cancer - MAGNITUDE Trial
FEATURING
Neal Shore,
Kim Chi
- 45 views
- April 13, 2022
ecancer
ESMO 2021 Highlights on Nivo With Alternatively Scheduled Ipi in 1L Treatment of Advanced RCC: PRISM Study
FEATURING
Naveen Vasudev
- 37 views
- October 22, 2021
ecancer
PARPi in Prostate Cancer: Case Based Testing and Clinical Decisions
FEATURING
Neal Shore,
Fred Saad
- 375 views
- October 20, 2021
- 3
ecancer
Advances in Prostate Cancer in the Last 10 Years and a Glimpse to the Future
- 239 views
- October 20, 2021
ecancer
ESMO 2021 Update on Enzalutamide + ADT in Men With mHSPC: Final OS Analysis From ARCHES Study
FEATURING
Andrew Armstrong
- 57 views
- October 20, 2021
ecancer
ESMO 2021 Updates in HSPC: OS Analysis From ARCHES, STAMPEDE, and PEACE-1 Trials
- 60 views
- October 20, 2021
ecancer
ESMO 2021: PARPi Data and Their Role in Mono/Combination Therapies
- 46 views
- October 20, 2021
ecancer
ESMO 2020 Update on Advanced PC: What Is the Efficacy of PARP Inhibitors? When to Test for Gene Mutations?
- 126 views
- January 11, 2021
- 1
ecancer
ESMO Updates on Advanced RCC: Will Nivo+Cabozantinib Become a New SoC? Can We Detect ctDNA and How Can It Be Used in Diagnosis?
FEATURING
Toni Choueiri
- 99 views
- December 29, 2020
ecancer
ASCO IMvigor130 Updates on mUC: Does Atezo+/-Chemo Improve PFS/OS?
FEATURING
Matthew Galsky
- 20 views
- December 29, 2020
ecancer
2020 ESMO Update on nmCRPC: What Are the MFS Benefits With Apalutamide?
FEATURING
Heather Payne,
Stéphane Oudard
- 41 views
- December 7, 2020
ecancer
2020 ASCO Updates on Bladder Cancer: Should We Give IO in the Maintenance Setting or 2L at Progression? How Effective Are FGFRi? Can FGFR mRNA Over-Expression Help Identify Pts Who Can Benefit From Targeted Therapy?
FEATURING
Arlene Siefker-Radtke,
Yohann Loriot
- 128 views
- November 16, 2020
- 1
ecancer
2020 ASCO Update on PARPi in mCRPC: Is BRCA1/2 Correlated With the Best Outcomes to PARPi?
FEATURING
Emmanuel Antonarakis
- 69 views
- November 16, 2020
ecancer
2020 ESMO Update on PSMA-Targeted BITE IO in mCRPC: Could AMG 160 Sit in the Treatment Landscape of mCRPC?
FEATURING
Ben Tran
- 13 views
- October 29, 2020